M. Hogg

发表

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer

J. Valle, R. Swindell, B. Carrington, 2004, British Journal of Cancer.

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

M. Dowsett, M. Cheang, D. Rea, 2022, EBioMedicine.

Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

G. Jayson, D. Evans, E. Harkness, 2020, European Journal of Human Genetics.

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

J. Yarnold, J. Haviland, J. Bliss, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.